Key result
Low-dose aspirin administered from early pregnancy showed consistent evidence of a prophylactic role in preventing preeclampsia.
Why the study?
Preeclampsia is a leading cause of maternal and perinatal morbidity and mortality worldwide, prompting review of controversies and evidence regarding low-dose aspirin for its prevention.
Does low-dose aspirin from early pregnancy prevent preeclampsia in pregnant women?
Does low-dose aspirin from early pregnancy prevent preeclampsia in pregnant women?
This review highlights consistent evidence supporting the prophylactic use of low-dose aspirin from early pregnancy to prevent preeclampsia.
Low-dose aspirin from early pregnancy may reduce preeclampsia in high-risk women; leaves optimal dosing and timing open for prospective trials.
Preeclampsia is one of the leading causes of maternal and perinatal morbidity and mortality worldwide. In recent decades, many studies have evaluated different interventions in order to prevent the occurrence of preeclampsia. Among these, administration of low-dose aspirin from early pregnancy showed consistent evidence of its prophylactic role. In this article, we review the scientific literature on this topic, highlighting the rationale for aspirin use, who should be treated, the timing of initiation and cessation of therapy, the importance of proper dosing, and its role in the prevention of other adverse outcomes.
No takes yet. Share an insight, caveat, or question.
Amihai Rottenstreich (2024) conducted a review in Preeclampsia. Low-dose aspirin was evaluated on occurrence of preeclampsia. Low-dose aspirin administered from early pregnancy showed consistent evidence of a prophylactic role in preventing preeclampsia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: